Extended Data Fig. 1: TCGA database and public single-cell RNA-seq data analysis to determine expression pattern of YTHDF2 in cancers and tumor-infiltrating myeloid cells.

a, Boxplots showing the YTHDF2 expression in multiple types of cancers and corresponding normal tissues from RNA-seq results of the TCGA database. Red and blue boxes indicate the tumor group and normal group, respectively. The horizontal line indicates the median value; the box represents the first and third quartiles. Data were analyzed by two-sided unpaired wilcoxon test. b, Scatter plots showing an inverse Spearman’s correlation betweenYTHDF2 expression and immune scores calculated by the ESTIMATE algorithm from the TCGA database. Data are shown as a fitted line with 95% confidence level and were analyzed by linear model. c, The bubble plots showing the positive correlation of YTHDF2 expression with immune-related markers in each type of cancer. d-f, YTHDF2 expression in tumor-infiltrating myeloid cells and corresponding normal tissues from single-cell RNA-seq datasets of GBM (d), COAD (e), and BRCA (f). P values were calculated by two-sided unpaired wilcoxon test. Abbreviation for TCGA cancer types: BRCA, Breast invasive carcinoma; CHOL, Cholangiocarcinoma; COAD, Colon adenocarcinoma; DLBC, Lymphoid neoplasm diffuse large B-cell lymphoma; GBM, Glioblastoma multiforme; LGG, Brain lower grade glioma; PAAD, Pancreatic adenocarcinoma; READ, Rectum adenocarcinoma; SKCM, Skin cutaneous melanoma; STAD, Stomach adenocarcinoma; TGCT, Testicular germ cell tumors; THYM, Thymoma; UCEC, Uterine corpus endometrial carcinoma; UCS, Uterine carcinosarcoma.